[HTML][HTML] Single-dose psilocybin for a treatment-resistant episode of major depression
GM Goodwin, ST Aaronson, O Alvarez… - … England Journal of …, 2022 - Mass Medical Soc
Background Psilocybin is being studied for use in treatment-resistant depression. Methods
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
GM Goodwin, ST Aaronson, O Alvarez… - The New England …, 2022 - research.rug.nl
METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-
resistant depression to receive a single dose of a proprietary, synthetic formulation of …
resistant depression to receive a single dose of a proprietary, synthetic formulation of …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
GM Goodwin, ST Aaronson, O Alvarez… - The New England …, 2022 - europepmc.org
Methods In this phase 2 double-blind trial, we randomly assigned adults with treatment-
resistant depression to receive a single dose of a proprietary, synthetic formulation of …
resistant depression to receive a single dose of a proprietary, synthetic formulation of …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
GM Goodwin, ST Aaronson, O Alvarez… - The New England …, 2022 - eprints.ncl.ac.uk
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression - ePrints -
Newcastle University Newcastle University Toggle Main Menu Toggle Search Home Browse …
Newcastle University Newcastle University Toggle Main Menu Toggle Search Home Browse …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
GM Goodwin - 2022 - researchgate.net
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression Page 1 0 -5
-10 -15 -20 Least-SquaresMean Difference, −2.5 (95% CI, −6.2 to 1.2; P = 0.18) Difference, −6.6 …
-10 -15 -20 Least-SquaresMean Difference, −2.5 (95% CI, −6.2 to 1.2; P = 0.18) Difference, −6.6 …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
GM Goodwin, ST Aaronson, O Alvarez… - New England Journal …, 2022 - kclpure.kcl.ac.uk
BACKGROUND Psilocybin is being studied for use in treatment-resistant depression.
METHODS In this phase 2 double-blind trial, we randomly assigned adults with …
METHODS In this phase 2 double-blind trial, we randomly assigned adults with …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
GM Goodwin, ST Aaronson… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Psilocybin is being studied for use in treatment-resistant depression. Methods
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …
In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
GM Goodwin, ST Aaronson, O Alvarez… - The New England …, 2022 - vbn.aau.dk
BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression.
METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment …
METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment …
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
GM Goodwin, ST Aaronson, O Alvarez… - New England Journal …, 2022 - cir.nii.ac.jp
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …